Difference between revisions of "Nadofaragene firadenovec (Adstiladrin)"
Jump to navigation
Jump to search
(Created page with "==General information== From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nadofaragene-firadenovec NCI Drug Dictionary]: A replication-deficient recom...") |
m |
||
| Line 6: | Line 6: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *12 | + | *2022-12-16: Initial approval for adult patients with high-risk Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive [[bladder cancer]] (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ''(Based on rAd-IFN-CS-003)'' |
==Also known as== | ==Also known as== | ||
Revision as of 15:56, 21 April 2023
General information
From the NCI Drug Dictionary: A replication-deficient recombinant adenovirus encoding human interferon alpha-2b with potential antineoplastic activity. Upon intravesical administration, nadofaragene firadenovec infects nearby tumor cells and expresses INF alpha-2b intracellularly which activates the transcription and translation of genes whose products mediate antiviral, antiproliferative, antitumor, and immune-modulating effects.
Diseases for which it is used
History of changes in FDA indication
- 2022-12-16: Initial approval for adult patients with high-risk Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. (Based on rAd-IFN-CS-003)
Also known as
- Code name: SCH 721015
- Generic name: nadofaragene firadenovec-vncg
- Brand name: Adstiladrin, Instiladrin